AU6037499A - Methods of treating viral disease - Google Patents

Methods of treating viral disease

Info

Publication number
AU6037499A
AU6037499A AU60374/99A AU6037499A AU6037499A AU 6037499 A AU6037499 A AU 6037499A AU 60374/99 A AU60374/99 A AU 60374/99A AU 6037499 A AU6037499 A AU 6037499A AU 6037499 A AU6037499 A AU 6037499A
Authority
AU
Australia
Prior art keywords
methods
viral disease
treating viral
treating
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60374/99A
Inventor
Ann Kwong
Roger Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU6037499A publication Critical patent/AU6037499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
AU60374/99A 1998-09-14 1999-09-14 Methods of treating viral disease Abandoned AU6037499A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10014498P 1998-09-14 1998-09-14
US60100144 1998-09-14
US13842999P 1999-06-10 1999-06-10
US60138429 1999-06-10
PCT/US1999/021003 WO2000015210A2 (en) 1998-09-14 1999-09-14 Use of mycophenol acid and its derivatives for the treatment of virus diseases

Publications (1)

Publication Number Publication Date
AU6037499A true AU6037499A (en) 2000-04-03

Family

ID=26796841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60374/99A Abandoned AU6037499A (en) 1998-09-14 1999-09-14 Methods of treating viral disease

Country Status (4)

Country Link
EP (1) EP1113794A2 (en)
JP (1) JP2002524502A (en)
AU (1) AU6037499A (en)
WO (1) WO2000015210A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301771B6 (en) * 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Pharmaceutical formulation in the form of dry granulation product containing mycophenolate mofetil or mycophenolic acid and process for preparing thereof
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
DK0858343T3 (en) * 1995-11-02 2004-05-10 Schering Corp Continuous low dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy

Also Published As

Publication number Publication date
JP2002524502A (en) 2002-08-06
WO2000015210A3 (en) 2000-05-25
EP1113794A2 (en) 2001-07-11
WO2000015210A2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
EP1109580A4 (en) Methods for treating or preventing viral infections and associated diseases
GB9824436D0 (en) Methods of treatment
EP1115286A4 (en) Methods for treating or preventing viral infections and associated diseases
AU1189399A (en) Bathocuproine treatment of neurologic disease
AU3596199A (en) Treatment of celiac disease
AU1772399A (en) Well treatment
AU7165498A (en) Methods for treating viral infections
AU8451298A (en) Treatment of fabrics
AU5610198A (en) Compounds and methods for treating and preventing bacterial and viral disease
AU6883398A (en) Methods of treating bone loss
AU1570199A (en) Methods of lyophilizing solutions
EP1107778A4 (en) Treatment of disease states
AU6037499A (en) Methods of treating viral disease
AU4985200A (en) Methods of treating hypertension
AU7157598A (en) Method for the treatment of viral disease
IL138484A0 (en) Treatment of panic attacks
AU1353901A (en) Method of treating batten disease
AU5524399A (en) Inorgasmia treatment
AU9198898A (en) Methods for treating ocular diseases
PL346528A1 (en) Treatment of depression
AU6442998A (en) Method for the purification of virus
AU5753599A (en) Treatment of fibres
AU5294499A (en) Treatment of hair loss
AUPP363398A0 (en) Method of treatment
AUPP460798A0 (en) Method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase